Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

ASTRO and AAPM announce RO-ILS: Radiation Oncology Incident Learning System (RO-ILS)

Together, the American Society for Radiation Oncology (ASTRO) and the American Association of Physicists in Medicine (AAPM) will share details about RO-ILS: Radiation Oncology Incident Learning System, a new, national patient safety initiative to facilitate safer and higher quality radiation oncology care.

Personalized care from disease detection through treatment assessment enabled with GE Healthcare’s Discovery IQ

During the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE Healthcare introduced its Discovery IQ PET/CT system, enabling both outstanding image quality and intelligent quantitation, helping physicians deliver the best possible patient outcomes.

FDA approves Lymphoseek to help determine the extent of head and neck cancer in the body

The U.S. Food and Drug Administration today approved a new use for Lymphoseek (technetium 99m tilmanocept) Injection, a radioactive diagnostic imaging agent used to help doctors determine the extent a type of cancer called squamous cell carcinoma has spread in the body’s head and neck region.

GE Healthcare Launches Interactive Patient Profiler for AdreView (Iobenguane I 123 Injection)

The Interactive Patient Profiler for AdreView is a simulation tool designed to help educate physicians on the use of AdreView (Iobenguane I 123 Injection) to assess mortality risk in patients with heart failure. The tool demonstrates the types of patients where the use of AdreView can provide further information to assist physicians in identifying patients who may have a lower one- and two-year mortality risk, among groups of patients with similar profiles based on other clinical information.

Research on Piramal Imaging's Neuraceq (florbetaben F18 injection) takes center stage at SNMMI

Piramal Imaging released details from research presented at the Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), currently underway at St. Louis Convention Center in St. Louis, Mo.

Thumbnail

Highlights from the 2014 SNMMI Annual Meeting

Wednesday is the last day of the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting in St. Louis, but the news and images keep coming.

NorthStar Medical Technologies Signs Letter of Intent with Triad Isotopes To Bring New Domestic Source of Non-HEU Materials To Market

NorthStar Medical Technologies, LLC today announced the signing of a non-exclusive Letter of Intent with Triad Isotopes, Inc.  The agreement solidifies Triad’s position as an early adopter of domestically-sourced Non-HEU Molybdenum99 through NorthStar’s unique intelligent isotope separation systems, once that technology is approved by the FDA and commercially available.

Philips Drives Digital Innovation with Vereos at Society of Nuclear Medicine and Molecular Imaging Annual Meeting

Royal Philips today introduced Vereos PET/CT, the first digital PET/CT scanner, at the 2014 annual meeting of the Society of Nuclear Medicine and Molecular Imaging  (SNMMI), taking place this week in St. Louis, Mo.  In addition to Vereos, Philips will showcase a selection of innovative, molecular imaging solutions designed to deliver outstanding image quality, critical clinical information and greater connectivity.